Evidence map›Paper›PMID 37458446›Full record

ArticleMicrobiology resource announcements2023

Draft genomes of

E Anne Hatmaker, Jonathan E Schmitz, Antonis Rokas

Open access · diamondAbstract read
In one paragraph

Article in Microbiology resource announcements, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

E Anne HatmakerDepartment of Biological Sciences, Vanderbilt University , Nashville, Tennessee, USA.ORCID 0000-0002-7821-8160
Jonathan E SchmitzDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center , Nashville, Tennessee, USA.ORCID 0000-0002-2727-9078
Antonis RokasDepartment of Biological Sciences, Vanderbilt University , Nashville, Tennessee, USA.ORCID 0000-0002-7248-6551
Vanderbilt University · USVanderbilt Health · US

Funding

Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
Deciphering the phenotypic and genomic traits that underlie the evolution of pathogenicity differences among Aspergillus fumigatus and its close relativesR01AI153356 · NIAID · VANDERBILT UNIVERSITY · PI Antonis Rokas · 2022 to 2026
$3.5M
The Vanderbilt Urologic Infection Repository, a Resource for Personalized Clinical DiscoveryP20DK123967 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HADJIFRANGISKOU, MARIA · 2019 to 2020
$680k
Examining the role of opportunistic human pathogen Aspergillus flavus in fungal keratitis eye infectionsF31EY033235 · NEI · VANDERBILT UNIVERSITY · PI HATMAKER, ELIZABETH ANNE · 2022 to 2023
$42k
NCATS NIH HHS UL1 TR002243NEI NIH HHS F31 EY033235NIAID NIH HHS R01 AI153356NIDDK NIH HHS P20 DK123967
6 · The paper itself

Abstract

Fungal species within the genus

Indexed as

AspergillusAspergillus flavusclinical isolatefungal keratitispathogenicity

Identifiers

PMID37458446
PMCPMC10508098
OpenAlexW4384523255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.